News
Clinical Trials Arena on MSN2d
Monument Therapeutics to trial schizophrenia therapy in partnership with FNIH
UK-based Monument Therapeutics has joined forces with the Foundation for the National Institutes of Health (FNIH), US, to ...
UK-based Monument Therapeutics has partnered with the US Foundation for the National Institutes of Health (FNIH) to study MT1988, which is under development for treating cognitive impairment in ...
Cambridge Cognition said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for ...
(Alliance News) - Cambridge Cognition Holdings PLC on Tuesday said Monument Therapeutics, in which it holds a 20% stake, has partnered up on the development of a novel treatment for cognitive ...
CAMBRIDGE, UK - Monument Therapeutics has partnered with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment for cognitive impairment associated with ...
The AIM-traded firm said the clinical study would evaluate MT1988, a novel therapy targeting cognitive impairment associated with schizophrenia, in a proof-of-principle trial under the ...
CAMBRIDGE, UK - Monument Therapeutics has partnered with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment for cognitive impairment associated with ...
UK-based Monument Therapeutics has partnered with the US Foundation for the National Institutes of Health (FNIH) to study MT1988, which is under development for treating cognitive impairment in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback